Navigation Links
CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
Date:12/17/2013

COPENHAGEN, Denmark; SEATTLE; STRASBOURG, France; and SAN FRANCISCO, Dec. 17, 2013 /PRNewswire/ -- CMC Biologics and OncoSynergy announced today that the two companies entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy's OS2966 monoclonal antibody program based on its "Targeted Synergy" approach - a transformative strategy allowing broad inhibition of multiple fundamental cancer growth mechanisms with a single drug.

(Logo: http://photos.prnewswire.com/prnh/20131217/SF34565LOGO)

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"We look forward to helping advance OncoSynergy's OS2966 drug platform targeting cancers resistant to currently available therapies," said Gustavo Mahler, Global Chief Operations Officer of CMC Biologics. "This contract highlights CMC Biologics' proven and trusted platform for monoclonal antibody development and manufacturing." 

The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

"We are impressed with CMC Biologics' experience and technical competency in biopharmaceutical development and cGMP manufacturing," said OncoSynergy Co-Founder and CEO, Shawn Carbonell, MD, PhD. "Choosing a partner who can provide a complete solution - from expression of the sequence of interest, to providing material suitable for clinical trials - was a critical decision as we advance our lead candidate. They have also shown flexibility to accommodate our unique program needs as a virtual startup company."

About OncoSynergy
OncoSynergy is a privately-held biotechnology company based in San Francisco, California and Strasbourg, France. The mission of OncoSynergy is to radically improve health outcomes for patients by addressing unmet needs in oncology and neurofibromatosis. Its therapies are drug platforms featuring "Targeted Synergy" - multiple mechanisms of action for maximal effectiveness. OncoSynergy's lead drug, OS2966, blocks a critical path for growth and therapy resistance in cancer and is under development for the treatment of glioblastoma. OncoSynergy's therapeutic platforms have been developed at several world-class institutions including by its founders at UCSF and by Martin Karplus of Harvard University - a 2013 Nobel Prize in Chemistryawardee. To learn more, visit www.oncosynergy.com.

About CMC Biologics 
CMC Biologics is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. To learn more, visit www.cmcbiologics.com.

Media Contacts:
Stacie D. Byars
CMC Biologics Global Marketing
sbyars@cmcbio.com
+1 (206) 660-2588

Robert Dunkle
OncoSynergy, Inc.
bob@oncosynergy.com
+1 (415) 978-2153


'/>"/>
SOURCE CMC Biologics; OncoSynergy
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
2. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
3. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
4. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
5. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
6. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
7. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
8. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
9. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
10. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
11. Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
Breaking Medicine News(10 mins):